Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Hold Rating, Announces Target Price $3
Cautious Optimism Amidst Uncertainty: Assessing Amylyx Pharmaceuticals' Future Prospects
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Taysha Gene Therapies (TSHA) and Lexeo Therapeutics, Inc. (LXEO)
Bank of America Securities Keeps Their Hold Rating on Amylyx Pharmaceuticals Inc (AMLX)
Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration
We Think Amylyx Pharmaceuticals (NASDAQ:AMLX) Can Easily Afford To Drive Business Growth
Earnings Call Summary | Amylyx Pharmaceuticals(AMLX.US) Q2 2024 Earnings Conference
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2024 Earnings Call Transcript
Buy Rating Affirmed for Amylyx Pharmaceuticals Amid Promising Drug Trials and FDA Breakthrough Designation
Amylyx Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Express News | Amylyx Pharma Q2 2024 Adj. EPS $(0.73), Inline,
Express News | Amylyx Pharmaceuticals Inc: Restructuring Expenses Were $22.9 Mln for Three Months Ended June 30, 2024
Amylyx Pharmaceuticals 2Q Rev Negative $1.02M >AMLX
Express News | Amylyx Pharmaceuticals Inc: Cash Runway Expected Into 2026
Amylyx Pharmaceuticals 2Q Loss $72.7M >AMLX
Express News | Amylyx Pharmaceuticals Q2 Operating Income USD -76.286 Million
Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results
Press Release: Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results
Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
Express News | Amylyx Pharmaceuticals Announces European Commission Grants Orphan Drug Designation For AMX0035 For Wolfram Syndrome; Topline Data From Phase 2 HELIOS Trial Expected Fall 2024